Key points from article :
Poietis aims to address issues of implantable tissues, such as standardization, product reproducibility, and scaling up.
Fabien Guillemot (CEO of Poietis) and Bruno Brisson (co-founder of Poietis) detail the Next Generation Bioprinting (NGB) platform.
Printing and manufacturing phase is automated and robotized.
Benefits: affordable treatment; controlling architecture to increase functionality
Apart from skin, NGB platform can be used for other cell and tissue types.
Equipped with Stäubli’s robotic arm for moving the tissue under construction from one printing head to another.
Skin substitutes included both epidermis and dermis — not feasible at the artisanal level.
Before automation, it took about 8-9 hours to manufacture a 40 cm2 square of skin; while it takes only 3-4 hours after automation.
Phase I–II project probably in dozens of patients with wounds, small burns and traumatic wounds.
World’s first clinical trial of bioprinted skin graft will start in 2022 at the University Hospital of Marseille.
